Page last updated: 2024-07-31 20:29:11
sanorg 34006
Description
idraparinux: a synthetic analogue of the pentasaccharide sequence in heparins [MeSH]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 3083444 |
| MeSH ID | M0291233 |
Synonyms (23)
| Synonym |
|---|
| idraparinux sodium [usan:inn] |
| methyl o-2,3,4-tri-o-methyl-6-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-beta-d-glucopyranuronosyl-(1-4)-o-2,3,6-tri-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-alpha-l-idopyranuronosyl-(1-4)-2,3,6-tri-o-sulfo-alpha-d-glucopyranosid |
| unii-h84ixp29fn |
| 149920-56-9 |
| alpha-d-glucopyranoside, methyl o-2,3,4-tri-o-methyl-6-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-beta-d-glucopyranuronosyl-(1-4)-o-2,3,6-tri-o-sulfo-alpha-d-glucopyranosyl-(1-4)-o-2,3-di-o-methyl-alpha-l-idopyranuranosyl-(1-4)-, 2,3,6-tris(hy |
| sanorg34006 |
| h84ixp29fn , |
| s-o-34006 |
| org-34006 |
| idraparinux sodium |
| sanorg-34006 |
| org 34006 |
| sanorg 34006 |
| idraparinux |
| idraparinux sodium (usan) |
| D10471 |
| idraparinux sodium [inn] |
| idraparinux sodium [who-dd] |
| idraparinux nonasodium salt [mi] |
| idraparinux sodium [mart.] |
| methyl (sodium 2,3,4-tri-o-methyl-6-o-sulfonato-.alpha.-d-glucopyranosyl)-(1->4)-(sodium 2,3-di-o-methyl-.beta.-d-glucopyranosylurate)-(1->4)-(trisodium 2,3,6-tri-o-sulfonato-.alpha.-d-glucopyranosyl)-(1->4)-(sodium -2,3-di-o-methyl-.alpha.-l-idopyranosyl |
| idraparinux sodium [usan] |
| Q3147909 |
Research
Studies (89)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.25) | 18.2507 |
| 2000's | 56 (62.92) | 29.6817 |
| 2010's | 31 (34.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 14 (15.73%) | 5.53% |
| Reviews | 42 (47.19%) | 6.00% |
| Case Studies | 1 (1.12%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 32 (35.96%) | 84.16% |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Acute Coronary Syndrome | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Liver Injury, Drug-Induced | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Age-Related Osteoporosis | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Angiogenesis, Pathologic | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Apoplexy | 0 | | 2004 | 2016 | 14.1 | low | 6 | 0 | 0 | 8 | 7 | 0 |
| Atrial Fibrillation | 0 | | 2004 | 2016 | 14.7 | low | 7 | 0 | 0 | 15 | 8 | 0 |
| Auricular Fibrillation | 0 | | 2004 | 2016 | 14.7 | low | 7 | 0 | 0 | 15 | 8 | 0 |
| Autoimmune Thrombocytopenia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bacterial Pneumonia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Benign Neoplasms | 0 | | 2003 | 2019 | 11.2 | low | 1 | 0 | 0 | 2 | 3 | 0 |
| Bleeding | 0 | | 2004 | 2019 | 13.1 | low | 10 | 0 | 0 | 11 | 11 | 0 |
| Blood Clot | 0 | | 1998 | 2009 | 18.6 | low | 0 | 0 | 1 | 10 | 0 | 0 |
| Blood Coagulation Disorders | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bone Fractures | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Ischemia | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bullous Dermatoses | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Lung | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cardiac Cancer | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cardiac Failure | 0 | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Cardiovascular Diseases | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Cardiovascular Stroke | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cerebral Ischemia | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chemical and Drug Induced Liver Injury | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Kidney Diseases | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Cirrhosis, Liver | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Coagulation Disorders, Blood | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Community Acquired Infection | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Coronary Disease | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Coronary Heart Disease | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Deep Vein Thrombosis | 0 | | 2003 | 2019 | 16.1 | low | 7 | 0 | 0 | 16 | 4 | 0 |
| Diabetes Mellitus, Adult-Onset | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Diabetes Mellitus, Type 2 | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Disease Models, Animal | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Embolism | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Embolism, Pulmonary | 0 | | 2004 | 2019 | 16.1 | low | 3 | 0 | 0 | 10 | 2 | 0 |
| Embolus | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Fractures, Bone | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Heart Disease, Ischemic | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Heart Failure | 0 | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Hemoptysis | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hemorrhage | 0 | | 2004 | 2019 | 13.1 | low | 10 | 0 | 0 | 11 | 11 | 0 |
| Kidney Failure | 0 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Liver Cirrhosis | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lung Neoplasms | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Myocardial Infarction | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Myocardial Ischemia | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neoplasms | 0 | | 2003 | 2019 | 11.2 | low | 1 | 0 | 0 | 2 | 3 | 0 |
| Obesity | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Osteoporosis | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Overweight | 0 | | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Peritonitis | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pneumonia, Bacterial | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Postphlebitic Disease | 0 | | 2006 | 2008 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Primary Peritonitis | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pulmonary Embolism | 0 | | 2004 | 2019 | 16.1 | low | 3 | 0 | 0 | 10 | 2 | 0 |
| Purpura, Thrombocytopenic, Idiopathic | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Recrudescence | 0 | | 2005 | 2017 | 15.1 | low | 3 | 0 | 0 | 6 | 2 | 0 |
| Renal Insufficiency | 0 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Renal Insufficiency, Chronic | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Stroke | 0 | | 2004 | 2016 | 14.1 | low | 6 | 0 | 0 | 8 | 7 | 0 |
| Thoracic Diseases | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Thrombocytopenia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Thromboembolism | 0 | | 2004 | 2015 | 16.9 | low | 1 | 0 | 0 | 16 | 2 | 0 |
| Thromboembolism, Venous | 0 | | 2008 | 2019 | 12.5 | low | 0 | 0 | 0 | 6 | 5 | 0 |
| Thrombopenia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Thrombosis | 0 | | 1998 | 2009 | 18.6 | low | 0 | 0 | 1 | 10 | 0 | 0 |
| Venous Thromboembolism | 0 | | 2008 | 2019 | 12.5 | low | 0 | 0 | 0 | 6 | 5 | 0 |
| Venous Thrombosis | 0 | | 2003 | 2019 | 16.1 | low | 7 | 0 | 0 | 16 | 4 | 0 |
Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.International journal of cardiology, , Oct-15, Volume: 221, 2016
Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial.Stroke, , Volume: 47, Issue:2, 2016
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.Journal of cardiology, , Volume: 66, Issue:6, 2015
Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial.European heart journal, , Volume: 34, Issue:46, 2013
Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.Chest, , Volume: 144, Issue:6, 2013
Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients.Journal of the American College of Cardiology, , Jan-22, Volume: 61, Issue:3, 2013
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.Archives of internal medicine, , Apr-23, Volume: 172, Issue:8, 2012
Bleeding risk in patients with atrial fibrillation: the AMADEUS study.Chest, , Volume: 140, Issue:1, 2011
New anticoagulants for atrial fibrillation.Seminars in thrombosis and hemostasis, , Volume: 35, Issue:5, 2009
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.Thrombosis and haemostasis, , Volume: 102, Issue:5, 2009
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.Journal of thrombosis and haemostasis : JTH, , Volume: 7, Issue:4, 2009
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.Seminars in thrombosis and hemostasis, , Volume: 34, Issue:1, 2008
Stroke prevention in atrial fibrillation: another step sideways.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Brave new world: the current and future use of novel anticoagulants.Thrombosis research, , Volume: 123 Suppl 1, 2008
Idraparinux for stroke prevention in atrial fibrillation.The Lancet. Neurology, , Volume: 7, Issue:4, 2008
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.Expert opinion on investigational drugs, , Volume: 17, Issue:5, 2008
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
[Update on the prevention of thromboembolic phenomena in atrial fibrillation].Revista medica de Chile, , Volume: 135, Issue:8, 2007
Clinical trials of new anticoagulants.Vnitrni lekarstvi, , Volume: 52 Suppl 1, 2006
[Preventing cerebrovascular accidents during atrial fibrillation].Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa.The American journal of medicine, , Volume: 118, Issue:10, 2005
Preparing for the post-warfarin generation of antithrombotics.The American journal of managed care, , Volume: 10, Issue:10 Suppl, 2004
New possibilities in anticoagulant management of atrial fibrillation.Reviews in cardiovascular medicine, , Volume: 5 Suppl 5, 2004
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5, 2019
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.The Cochrane database of systematic reviews, , 06-19, Volume: 6, 2018
Pentasaccharides for the treatment of deep vein thrombosis.The Cochrane database of systematic reviews, , 12-02, Volume: 12, 2017
Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.International journal of cardiology, , Oct-15, Volume: 221, 2016
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.Journal of cardiology, , Volume: 66, Issue:6, 2015
Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients.Journal of the American College of Cardiology, , Jan-22, Volume: 61, Issue:3, 2013
Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.Chest, , Volume: 144, Issue:6, 2013
Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial.European heart journal, , Volume: 34, Issue:46, 2013
Reversing anticoagulant therapy.Current drug discovery technologies, , Jun-01, Volume: 9, Issue:2, 2012
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.Journal of thrombosis and haemostasis : JTH, , Volume: 9, Issue:1, 2011
Bleeding risk in patients with atrial fibrillation: the AMADEUS study.Chest, , Volume: 140, Issue:1, 2011
Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.The Annals of pharmacotherapy, , Volume: 44, Issue:4, 2010
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.Thrombosis and haemostasis, , Volume: 104, Issue:1, 2010
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.Thrombosis and haemostasis, , Volume: 102, Issue:5, 2009
Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials.Journal of thrombosis and haemostasis : JTH, , Volume: 6, Issue:5, 2008
Stroke prevention in atrial fibrillation: another step sideways.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Idraparinux versus standard therapy for venous thromboembolic disease.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Extended prophylaxis of venous thromboembolism with idraparinux.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa.The American journal of medicine, , Volume: 118, Issue:10, 2005
Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.Seminars in vascular medicine, , Volume: 5, Issue:3, 2005
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.Journal of thrombosis and haemostasis : JTH, , Volume: 2, Issue:1, 2004
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5, 2019
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.The Cochrane database of systematic reviews, , 06-19, Volume: 6, 2018
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.The Cochrane database of systematic reviews, , Jul-08, Issue:7, 2014
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.Thrombosis and haemostasis, , Volume: 104, Issue:1, 2010
Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, Italy.IDrugs : the investigational drugs journal, , Volume: 6, Issue:11, 2003
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5, 2019
[New anticoagulants in the prevention and treatment of venous thromboembolism].Orvosi hetilap, , Jun-19, Volume: 152, Issue:25, 2011
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.Journal of thrombosis and haemostasis : JTH, , Volume: 7, Issue:4, 2009
[Update in hospital internal medicine (2007): a selection].Revue medicale suisse, , Jan-30, Volume: 4, Issue:142, 2008
[New large-scale studies with idraparinux, a prolonged action anticoagulant active via parenteral administration].Journal des maladies vasculaires, , Volume: 33, Issue:2, 2008
Extended prophylaxis of venous thromboembolism with idraparinux.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Idraparinux versus standard therapy for venous thromboembolic disease.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Agents to control bleeding show promise.JAMA, , Jan-24, Volume: 297, Issue:4, 2007
Emerging anticoagulants for the treatment of venous thromboembolism.Thrombosis and haemostasis, , Volume: 96, Issue:3, 2006
Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa.The American journal of medicine, , Volume: 118, Issue:10, 2005
New anticoagulants for treatment of venous thromboembolism.Circulation, , Aug-31, Volume: 110, Issue:9 Suppl 1, 2004
[Novel antithrombotic drugs. From the 19th Congress of the International Society on Thrombosis and Haemostasis].Kardiologiia, , Volume: 44, Issue:3, 2004
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.Journal of cardiology, , Volume: 66, Issue:6, 2015
The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.The Journal of pharmacology and experimental therapeutics, , Volume: 338, Issue:2, 2011
What can ongoing clinical trials of anticoagulants demonstrate?Journal of cardiovascular medicine (Hagerstown, Md.), , Volume: 10, Issue:8, 2009
Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?Thrombosis and haemostasis, , Volume: 101, Issue:3, 2009
Cutaneous blood-filled vesicles on idraparinux.Lancet (London, England), , Dec-06, Volume: 372, Issue:9654, 2008
Stroke prevention in atrial fibrillation: another step sideways.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.Expert opinion on investigational drugs, , Volume: 17, Issue:5, 2008
[Update on the prevention of thromboembolic phenomena in atrial fibrillation].Revista medica de Chile, , Volume: 135, Issue:8, 2007
Clinical trials of new anticoagulants.Vnitrni lekarstvi, , Volume: 52 Suppl 1, 2006
Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.Expert opinion on investigational drugs, , Volume: 15, Issue:8, 2006
Emerging anticoagulants for the treatment of venous thromboembolism.Thrombosis and haemostasis, , Volume: 96, Issue:3, 2006
New anticoagulants for the prevention and treatment of venous thromboembolism.Vascular health and risk management, , Volume: 1, Issue:1, 2005
[Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs].Recenti progressi in medicina, , Volume: 96, Issue:4, 2005
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].Kardiologiia, , Volume: 45, Issue:12, 2005
New anticoagulants for treatment of venous thromboembolism.Circulation, , Aug-31, Volume: 110, Issue:9 Suppl 1, 2004
Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.Current opinion in pulmonary medicine, , Volume: 10, Issue:5, 2004
[Novel antithrombotic drugs. From the 19th Congress of the International Society on Thrombosis and Haemostasis].Kardiologiia, , Volume: 44, Issue:3, 2004
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.Thrombosis and haemostasis, , Volume: 102, Issue:5, 2009
From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.Thrombosis and haemostasis, , Volume: 102, Issue:5, 2009
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.Seminars in thrombosis and hemostasis, , Volume: 34, Issue:1, 2008
Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.Journal of thrombosis and haemostasis : JTH, , Volume: 6, Issue:10, 2008
Clinical trials of new anticoagulants.Vnitrni lekarstvi, , Volume: 52 Suppl 1, 2006
[New antithrombotic drugs: fondaparinux, idraparinux, ximelagatran].Przeglad lekarski, , Volume: 62, Issue:8, 2005
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].Kardiologiia, , Volume: 45, Issue:12, 2005
Idraparinux sodium: SANORG 34006, SR 34006.Drugs in R&D, , Volume: 5, Issue:3, 2004
Idraparinux sodium. Sanofi-Aventis.IDrugs : the investigational drugs journal, , Volume: 7, Issue:11, 2004
Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, Italy.IDrugs : the investigational drugs journal, , Volume: 6, Issue:11, 2003
Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.Blood, , Jun-01, Volume: 91, Issue:11, 1998
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5, 2019
Pentasaccharides for the treatment of deep vein thrombosis.The Cochrane database of systematic reviews, , 12-02, Volume: 12, 2017
Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.British journal of clinical pharmacology, , Volume: 75, Issue:5, 2013
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.Journal of thrombosis and haemostasis : JTH, , Volume: 9, Issue:1, 2011
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.Thrombosis and haemostasis, , Volume: 104, Issue:1, 2010
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.Journal of thrombosis and haemostasis : JTH, , Volume: 7, Issue:4, 2009
[Update in hospital internal medicine (2007): a selection].Revue medicale suisse, , Jan-30, Volume: 4, Issue:142, 2008
[New large-scale studies with idraparinux, a prolonged action anticoagulant active via parenteral administration].Journal des maladies vasculaires, , Volume: 33, Issue:2, 2008
Extended prophylaxis of venous thromboembolism with idraparinux.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Idraparinux versus standard therapy for venous thromboembolic disease.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Agents to control bleeding show promise.JAMA, , Jan-24, Volume: 297, Issue:4, 2007
Emerging anticoagulants for the treatment of venous thromboembolism.Thrombosis and haemostasis, , Volume: 96, Issue:3, 2006
Clinical trials of new anticoagulants.Vnitrni lekarstvi, , Volume: 52 Suppl 1, 2006
Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.Seminars in vascular medicine, , Volume: 5, Issue:3, 2005
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].Kardiologiia, , Volume: 45, Issue:12, 2005
New anticoagulants for the prevention and treatment of venous thromboembolism.Vascular health and risk management, , Volume: 1, Issue:1, 2005
New anticoagulants for treatment of venous thromboembolism.Circulation, , Aug-31, Volume: 110, Issue:9 Suppl 1, 2004
Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.Current opinion in pulmonary medicine, , Volume: 10, Issue:5, 2004
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.Journal of thrombosis and haemostasis : JTH, , Volume: 2, Issue:1, 2004
Idraparinux and liver enzymes: observations from the PERSIST trial.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, , Volume: 14, Issue:1, 2003
Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial.Stroke, , Volume: 47, Issue:2, 2016
Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.International journal of cardiology, , Oct-15, Volume: 221, 2016
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.Journal of cardiology, , Volume: 66, Issue:6, 2015
Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial.European heart journal, , Volume: 34, Issue:46, 2013
Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.Chest, , Volume: 144, Issue:6, 2013
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.Archives of internal medicine, , Apr-23, Volume: 172, Issue:8, 2012
Bleeding risk in patients with atrial fibrillation: the AMADEUS study.Chest, , Volume: 140, Issue:1, 2011
[Update in hospital internal medicine (2007): a selection].Revue medicale suisse, , Jan-30, Volume: 4, Issue:142, 2008
Idraparinux for stroke prevention in atrial fibrillation.The Lancet. Neurology, , Volume: 7, Issue:4, 2008
Stroke prevention in atrial fibrillation: another step sideways.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Brave new world: the current and future use of novel anticoagulants.Thrombosis research, , Volume: 123 Suppl 1, 2008
[Preventing cerebrovascular accidents during atrial fibrillation].Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
Preparing for the post-warfarin generation of antithrombotics.The American journal of managed care, , Volume: 10, Issue:10 Suppl, 2004
New possibilities in anticoagulant management of atrial fibrillation.Reviews in cardiovascular medicine, , Volume: 5 Suppl 5, 2004
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5, 2019
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.The Cochrane database of systematic reviews, , 06-19, Volume: 6, 2018
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.The Cochrane database of systematic reviews, , Jul-08, Issue:7, 2014
Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.PloS one, , Volume: 8, Issue:11, 2013
[New anticoagulants in the prevention and treatment of venous thromboembolism].Orvosi hetilap, , Jun-19, Volume: 152, Issue:25, 2011
New anticoagulants for prevention and treatment of venous thromboembolism.Current vascular pharmacology, , Volume: 8, Issue:3, 2010
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.Clinics in chest medicine, , Volume: 31, Issue:4, 2010
New anticoagulants for treatment of venous thromboembolism.Arteriosclerosis, thrombosis, and vascular biology, , Volume: 28, Issue:3, 2008
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.Seminars in thrombosis and hemostasis, , Volume: 34, Issue:1, 2008
Brave new world: the current and future use of novel anticoagulants.Thrombosis research, , Volume: 123 Suppl 1, 2008
Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.European journal of clinical pharmacology, , Volume: 64, Issue:6, 2008
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5, 2019
Pentasaccharides for the treatment of deep vein thrombosis.The Cochrane database of systematic reviews, , 12-02, Volume: 12, 2017
Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.British journal of clinical pharmacology, , Volume: 75, Issue:5, 2013
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.Journal of thrombosis and haemostasis : JTH, , Volume: 9, Issue:1, 2011
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.Thrombosis and haemostasis, , Volume: 104, Issue:1, 2010
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.Journal of thrombosis and haemostasis : JTH, , Volume: 7, Issue:4, 2009
[New large-scale studies with idraparinux, a prolonged action anticoagulant active via parenteral administration].Journal des maladies vasculaires, , Volume: 33, Issue:2, 2008
[Update in hospital internal medicine (2007): a selection].Revue medicale suisse, , Jan-30, Volume: 4, Issue:142, 2008
Extended prophylaxis of venous thromboembolism with idraparinux.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Idraparinux versus standard therapy for venous thromboembolic disease.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Agents to control bleeding show promise.JAMA, , Jan-24, Volume: 297, Issue:4, 2007
Clinical trials of new anticoagulants.Vnitrni lekarstvi, , Volume: 52 Suppl 1, 2006
Emerging anticoagulants for the treatment of venous thromboembolism.Thrombosis and haemostasis, , Volume: 96, Issue:3, 2006
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].Kardiologiia, , Volume: 45, Issue:12, 2005
Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.Seminars in vascular medicine, , Volume: 5, Issue:3, 2005
New anticoagulants for the prevention and treatment of venous thromboembolism.Vascular health and risk management, , Volume: 1, Issue:1, 2005
New anticoagulants for treatment of venous thromboembolism.Circulation, , Aug-31, Volume: 110, Issue:9 Suppl 1, 2004
Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.Current opinion in pulmonary medicine, , Volume: 10, Issue:5, 2004
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.Journal of thrombosis and haemostasis : JTH, , Volume: 2, Issue:1, 2004
Idraparinux and liver enzymes: observations from the PERSIST trial.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, , Volume: 14, Issue:1, 2003
Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial.Stroke, , Volume: 47, Issue:2, 2016
Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.International journal of cardiology, , Oct-15, Volume: 221, 2016
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.Journal of cardiology, , Volume: 66, Issue:6, 2015
Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.Chest, , Volume: 144, Issue:6, 2013
Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial.European heart journal, , Volume: 34, Issue:46, 2013
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.Archives of internal medicine, , Apr-23, Volume: 172, Issue:8, 2012
Bleeding risk in patients with atrial fibrillation: the AMADEUS study.Chest, , Volume: 140, Issue:1, 2011
Stroke prevention in atrial fibrillation: another step sideways.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Brave new world: the current and future use of novel anticoagulants.Thrombosis research, , Volume: 123 Suppl 1, 2008
[Update in hospital internal medicine (2007): a selection].Revue medicale suisse, , Jan-30, Volume: 4, Issue:142, 2008
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Idraparinux for stroke prevention in atrial fibrillation.The Lancet. Neurology, , Volume: 7, Issue:4, 2008
[Preventing cerebrovascular accidents during atrial fibrillation].Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
New possibilities in anticoagulant management of atrial fibrillation.Reviews in cardiovascular medicine, , Volume: 5 Suppl 5, 2004
Preparing for the post-warfarin generation of antithrombotics.The American journal of managed care, , Volume: 10, Issue:10 Suppl, 2004
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5, 2019
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.The Cochrane database of systematic reviews, , 06-19, Volume: 6, 2018
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.The Cochrane database of systematic reviews, , Jul-08, Issue:7, 2014
Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials.PloS one, , Volume: 8, Issue:11, 2013
[New anticoagulants in the prevention and treatment of venous thromboembolism].Orvosi hetilap, , Jun-19, Volume: 152, Issue:25, 2011
New anticoagulants for prevention and treatment of venous thromboembolism.Current vascular pharmacology, , Volume: 8, Issue:3, 2010
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.Clinics in chest medicine, , Volume: 31, Issue:4, 2010
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.Seminars in thrombosis and hemostasis, , Volume: 34, Issue:1, 2008
Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.European journal of clinical pharmacology, , Volume: 64, Issue:6, 2008
New anticoagulants for treatment of venous thromboembolism.Arteriosclerosis, thrombosis, and vascular biology, , Volume: 28, Issue:3, 2008
Brave new world: the current and future use of novel anticoagulants.Thrombosis research, , Volume: 123 Suppl 1, 2008
Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial.Stroke, , Volume: 47, Issue:2, 2016
Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.International journal of cardiology, , Oct-15, Volume: 221, 2016
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.Journal of cardiology, , Volume: 66, Issue:6, 2015
Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients.Journal of the American College of Cardiology, , Jan-22, Volume: 61, Issue:3, 2013
Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.Chest, , Volume: 144, Issue:6, 2013
Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial.European heart journal, , Volume: 34, Issue:46, 2013
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.Archives of internal medicine, , Apr-23, Volume: 172, Issue:8, 2012
Bleeding risk in patients with atrial fibrillation: the AMADEUS study.Chest, , Volume: 140, Issue:1, 2011
New anticoagulants for atrial fibrillation.Seminars in thrombosis and hemostasis, , Volume: 35, Issue:5, 2009
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.Thrombosis and haemostasis, , Volume: 102, Issue:5, 2009
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.Journal of thrombosis and haemostasis : JTH, , Volume: 7, Issue:4, 2009
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.Expert opinion on investigational drugs, , Volume: 17, Issue:5, 2008
Idraparinux for stroke prevention in atrial fibrillation.The Lancet. Neurology, , Volume: 7, Issue:4, 2008
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.Seminars in thrombosis and hemostasis, , Volume: 34, Issue:1, 2008
Stroke prevention in atrial fibrillation: another step sideways.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Brave new world: the current and future use of novel anticoagulants.Thrombosis research, , Volume: 123 Suppl 1, 2008
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
[Update on the prevention of thromboembolic phenomena in atrial fibrillation].Revista medica de Chile, , Volume: 135, Issue:8, 2007
Clinical trials of new anticoagulants.Vnitrni lekarstvi, , Volume: 52 Suppl 1, 2006
[Preventing cerebrovascular accidents during atrial fibrillation].Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa.The American journal of medicine, , Volume: 118, Issue:10, 2005
New possibilities in anticoagulant management of atrial fibrillation.Reviews in cardiovascular medicine, , Volume: 5 Suppl 5, 2004
Preparing for the post-warfarin generation of antithrombotics.The American journal of managed care, , Volume: 10, Issue:10 Suppl, 2004
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5, 2019
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.The Cochrane database of systematic reviews, , 06-19, Volume: 6, 2018
Pentasaccharides for the treatment of deep vein thrombosis.The Cochrane database of systematic reviews, , 12-02, Volume: 12, 2017
Predictive abilities of the HAS-BLED and ORBIT bleeding risk scores in non-warfarin anticoagulated atrial fibrillation patients: An ancillary analysis from the AMADEUS trial.International journal of cardiology, , Oct-15, Volume: 221, 2016
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.Journal of cardiology, , Volume: 66, Issue:6, 2015
Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial.European heart journal, , Volume: 34, Issue:46, 2013
Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study.Chest, , Volume: 144, Issue:6, 2013
Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients.Journal of the American College of Cardiology, , Jan-22, Volume: 61, Issue:3, 2013
Reversing anticoagulant therapy.Current drug discovery technologies, , Jun-01, Volume: 9, Issue:2, 2012
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.Journal of thrombosis and haemostasis : JTH, , Volume: 9, Issue:1, 2011
Bleeding risk in patients with atrial fibrillation: the AMADEUS study.Chest, , Volume: 140, Issue:1, 2011
Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.The Annals of pharmacotherapy, , Volume: 44, Issue:4, 2010
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.Thrombosis and haemostasis, , Volume: 104, Issue:1, 2010
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.Thrombosis and haemostasis, , Volume: 102, Issue:5, 2009
Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials.Journal of thrombosis and haemostasis : JTH, , Volume: 6, Issue:5, 2008
Stroke prevention in atrial fibrillation: another step sideways.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.Lancet (London, England), , Jan-26, Volume: 371, Issue:9609, 2008
Extended prophylaxis of venous thromboembolism with idraparinux.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Idraparinux versus standard therapy for venous thromboembolic disease.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa.The American journal of medicine, , Volume: 118, Issue:10, 2005
Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.Seminars in vascular medicine, , Volume: 5, Issue:3, 2005
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.Journal of thrombosis and haemostasis : JTH, , Volume: 2, Issue:1, 2004
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5, 2019
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.The Cochrane database of systematic reviews, , 06-19, Volume: 6, 2018
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.The Cochrane database of systematic reviews, , Jul-08, Issue:7, 2014
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.Thrombosis and haemostasis, , Volume: 104, Issue:1, 2010
Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, Italy.IDrugs : the investigational drugs journal, , Volume: 6, Issue:11, 2003
New anticoagulants for treatment of venous thromboembolism.Arteriosclerosis, thrombosis, and vascular biology, , Volume: 28, Issue:3, 2008
Emerging anticoagulants for the treatment of venous thromboembolism.Thrombosis and haemostasis, , Volume: 96, Issue:3, 2006
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5, 2019
[New anticoagulants in the prevention and treatment of venous thromboembolism].Orvosi hetilap, , Jun-19, Volume: 152, Issue:25, 2011
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.Journal of thrombosis and haemostasis : JTH, , Volume: 7, Issue:4, 2009
[New large-scale studies with idraparinux, a prolonged action anticoagulant active via parenteral administration].Journal des maladies vasculaires, , Volume: 33, Issue:2, 2008
[Update in hospital internal medicine (2007): a selection].Revue medicale suisse, , Jan-30, Volume: 4, Issue:142, 2008
Extended prophylaxis of venous thromboembolism with idraparinux.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Agents to control bleeding show promise.JAMA, , Jan-24, Volume: 297, Issue:4, 2007
Idraparinux versus standard therapy for venous thromboembolic disease.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Emerging anticoagulants for the treatment of venous thromboembolism.Thrombosis and haemostasis, , Volume: 96, Issue:3, 2006
Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa.The American journal of medicine, , Volume: 118, Issue:10, 2005
[Novel antithrombotic drugs. From the 19th Congress of the International Society on Thrombosis and Haemostasis].Kardiologiia, , Volume: 44, Issue:3, 2004
New anticoagulants for treatment of venous thromboembolism.Circulation, , Aug-31, Volume: 110, Issue:9 Suppl 1, 2004
Pentasaccharides for the treatment of deep vein thrombosis.The Cochrane database of systematic reviews, , 12-02, Volume: 12, 2017
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.Journal of thrombosis and haemostasis : JTH, , Volume: 9, Issue:1, 2011
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial.Thrombosis and haemostasis, , Volume: 104, Issue:1, 2010
Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials.Journal of thrombosis and haemostasis : JTH, , Volume: 6, Issue:5, 2008
Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.European journal of clinical pharmacology, , Volume: 64, Issue:6, 2008
Idraparinux versus standard therapy for venous thromboembolic disease.The New England journal of medicine, , Sep-13, Volume: 357, Issue:11, 2007
Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.Seminars in vascular medicine, , Volume: 5, Issue:3, 2005
[Preventing cerebrovascular accidents during atrial fibrillation].Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.Thrombosis and haemostasis, , Volume: 102, Issue:5, 2009
From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.Thrombosis and haemostasis, , Volume: 102, Issue:5, 2009
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.Seminars in thrombosis and hemostasis, , Volume: 34, Issue:1, 2008
Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.Journal of thrombosis and haemostasis : JTH, , Volume: 6, Issue:10, 2008
Clinical trials of new anticoagulants.Vnitrni lekarstvi, , Volume: 52 Suppl 1, 2006
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].Kardiologiia, , Volume: 45, Issue:12, 2005
[New antithrombotic drugs: fondaparinux, idraparinux, ximelagatran].Przeglad lekarski, , Volume: 62, Issue:8, 2005
Idraparinux sodium. Sanofi-Aventis.IDrugs : the investigational drugs journal, , Volume: 7, Issue:11, 2004
Idraparinux sodium: SANORG 34006, SR 34006.Drugs in R&D, , Volume: 5, Issue:3, 2004
Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, Italy.IDrugs : the investigational drugs journal, , Volume: 6, Issue:11, 2003
Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.Blood, , Jun-01, Volume: 91, Issue:11, 1998
Safety/Toxicity (4)
| Article | Year |
|---|
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 57, Issue:5 | 2019 |
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Journal of cardiology, , Volume: 66, Issue:6 | 2015 |
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
Journal of thrombosis and haemostasis : JTH, , Volume: 9, Issue:1 | 2011 |
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders.
Expert opinion on investigational drugs, , Volume: 17, Issue:5 | 2008 |
Long-term Use (1)
Pharmacokinetics (1)
Bioavailability (3)
| Article | Year |
|---|
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.
Journal of thrombosis and haemostasis : JTH, , Volume: 7, Issue:4 | 2009 |
Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy.
Journal of thrombosis and haemostasis : JTH, , Volume: 6, Issue:10 | 2008 |
Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
Blood, , Jun-01, Volume: 91, Issue:11 | 1998 |
Dosage (10)
| Article | Year |
|---|
Pentasaccharides for the treatment of deep vein thrombosis.
The Cochrane database of systematic reviews, , 12-02, Volume: 12 | 2017 |
Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis.
British journal of clinical pharmacology, , Volume: 75, Issue:5 | 2013 |
New anticoagulants for atrial fibrillation.
Seminars in thrombosis and hemostasis, , Volume: 35, Issue:5 | 2009 |
Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?
Thrombosis and haemostasis, , Volume: 101, Issue:3 | 2009 |
The new anticoagulants.
Perspectives in vascular surgery and endovascular therapy, , Volume: 19, Issue:3 | 2007 |
New anticoagulants for the prevention and treatment of venous thromboembolism.
Vascular health and risk management, , Volume: 1, Issue:1 | 2005 |
Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Seminars in vascular medicine, , Volume: 5, Issue:3 | 2005 |
[Prophylaxis and treatment of venous thromboembolism: the role of new antithrombotic drugs].
Recenti progressi in medicina, , Volume: 96, Issue:4 | 2005 |
New possibilities in anticoagulant management of atrial fibrillation.
Reviews in cardiovascular medicine, , Volume: 5 Suppl 5 | 2004 |
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.
Journal of thrombosis and haemostasis : JTH, , Volume: 2, Issue:1 | 2004 |